Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone, in Combination With Lenalidomide or Oral Cyclophosphamide in Patients With Newly Diagnosed Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 04 Oct 2017
At a glance
- Drugs Oprozomib (Primary) ; Cyclophosphamide; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amgen
- 27 Sep 2017 Planned End Date changed from 1 Nov 2017 to 1 Mar 2018.
- 27 Sep 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Dec 2017.
- 20 Jun 2017 Planned End Date changed from 1 Aug 2017 to 1 Nov 2017.